Topics

Genenta Science of Milan Raises $14.6 Million in Funding Led by China Investor

04:19 EDT 13 Sep 2019 | ChinaBio Today

Genenta Science, a Milan biotech, raised $14.6 million in its third funding, led by Shanghai's Qianzhan Investment Management (QZ) and Fidim, an Italian family fund. Genenta is developing gene therapies for cancer using autologous hematopoietic stem progenitor cells (HSPCs) that contain an engineered gene for a tumor-related cytokine. It aims to trigger interferon-α expression, preventing relapses by rebuilding the patient’s immune system within the tumor. The company's lead product is Temferon, which has started trials in patients with early relapse multiple myeloma and newly diagnosed glioblastoma multiforme. More details....

Share this with colleagues:

Original Article: Genenta Science of Milan Raises $14.6 Million in Funding Led by China Investor

NEXT ARTICLE

More From BioPortfolio on "Genenta Science of Milan Raises $14.6 Million in Funding Led by China Investor"

Quick Search

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...